Geisinger President And CEO To Make Announcement At HLTH Conference

DR. DAVID T. FEINBERG TO UNVEIL NEW INFORMATION REGARDING GEISINGER’S DNA SEQUENCING COMMUNITY HEALTH INITIATIVE

DANVILLE, Pa., May 1, 2018 /PRNewswire-USNewswire/ -- David T. Feinberg, M.D., MBA, Geisinger president and CEO, will make a major announcement during his presentation at the HLTH Conference, on May 6^th at the Aria in Las Vegas. Dr. Feinberg’s presentation, “What Really Matters,” delves into the importance of DNA sequencing and looks at how genomic codes as well as zip codes can affect a person’s health.

Capping off the presentation will be a major announcement regarding Geisinger’s next steps when it comes to precision health.

“We think it’s time to transition our successful genomics program beyond the realm of research and into routine clinical care for all of our patients,” Dr. Feinberg said.

Geisinger is considered a leader in precision medicine with the success of its MyCode Community Health Initiative, which has enrolled more than 200,000 patient-participants and is delivering medically relevant results to participants and their primary care doctors. Some Geisinger participants have had cancers detected earlier and heart disease identified, allowing doctors to treat these conditions before any clinical symptoms became present.

“We’re one of the only organizations taking a population approach to genomics through our MyCode project,” said Dr. Feinberg. “To me, what we’re doing is really anticipatory medicine. It’s coming up with medically actionable results and giving that information back to our patients.”

Geisinger’s pioneering efforts in conducting large-scale DNA sequencing have garnered international recognition. In 2014, Geisinger announced a major collaboration with Regeneron Pharmaceuticals to sequence the DNA of its MyCode participants. Geisinger’s decision in 2013 to report clinically actionable genomic results to research participants was the first large-scale genomics project. Five years later, other large national and international projects are now just getting started.

“No other health system is doing exome sequencing on this scale, and no one has the experience with clinical reporting of actionable genomic results that we now have,” Dr. Feinberg added.

HLTH is a four-day event that brings together the most innovative and disruptive companies, ideas, and solutions with those in the industry who are prepared to advance the quality of care, improve patient experience, and revitalize the aging healthcare infrastructure. Dr. Feinberg will deliver his presentation Sunday at 6:20 pm.

About Geisinger
Geisinger is an integrated health services organization widely recognized for its early adoptions of the electronic health record and the development of innovative care delivery models such as ProvenHealth Navigator®, ProvenCare® and ProvenExperience®. As one of the nation’s largest health service organizations, Geisinger serves more than 3 million residents throughout 45 counties in central, south-central and northeast Pennsylvania, and in southern New Jersey at AtlantiCare, a Malcolm Baldrige National Quality Award recipient. In 2017, the Geisinger Commonwealth School of Medicine and Geisinger Jersey Shore Hospital became the newest members of Geisinger. The physician-led system is comprised of approximately 30,000 employees, including nearly 1,600 employed physicians, 13 hospital campuses, two research centers, and a 583,000-member health plan, all of which leverage an estimated $12.7 billion positive impact on the Pennsylvania and New Jersey economies. Geisinger has repeatedly garnered national accolades for integration, quality and service. In addition to fulfilling its patient care mission, Geisinger has a long-standing commitment to medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.

CONTACT for Geisinger:
Wendy Wilson
570-840-0878
WKWilson@geisinger.edu